- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Can AbbVie's Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? | 19 | Insider Monkey | ||
| Mo | ADARx Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | HBM Healthcare erhöht Beteiligung an Adarx im Rahmen des Börsengangs | 5 | cash | ||
| Mo | HBM Healthcare Investments Raises Stake In ADARx Pharma | 5 | RTTNews | ||
| ADARX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | 532 | EQS Group (DE) | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| Fr | ADARx Pharmaceuticals surges following upsized IPO | 2 | Seeking Alpha | ||
| Fr | Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut | 2 | MedCity News | ||
| Fr | Adarx Pharmaceuticals: 55 % des Börsengangs an nur zehn Investoren zugeteilt | 3 | Investing.com Deutsch | ||
| Fr | ADARx Pharmaceuticals raises $446.3 million in upsized US IPO | 1 | Reuters | ||
| Fr | siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range | 2 | Renaissance Capital | ||
| Fr | ADARx scores upsized $446M IPO, while fellow RNA biotech City Therapeutics maps out Nasdaq plans | 3 | FierceBiotech | ||
| Fr | RNAi drug specialist ADARx raises $446M IPO | 1 | BioPharma Dive | ||
| Fr | ADARx Pharmaceuticals prices upsized IPO at $17 per share | 1 | Investing.com | ||
| Fr | ADARx Pharmaceuticals Inc.: ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering | 443 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing... ► Artikel lesen | |
| 22.09. | ADARx Pharmaceuticals, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 21.09. | ADARx, Trex, and Retension take aim at IPOs | - | pharmaphorum | ||
| 21.09. | ADARx Pharmaceuticals Prices IPO Of 21.875 Mln Shares Between $15.00 And $17.00/Share | 667 | AFX News | WASHINGTON (dpa-AFX) - ADARx Pharmaceuticals, Inc. revealed Monday that it has priced an initial public offering or IPO, of 21.875 million shares of its common stock between $15.00 and $17.00... ► Artikel lesen | |
| 21.09. | siRNA biotech ADARx Pharmaceuticals sets terms for $350 million IPO | 7 | Renaissance Capital | ||
| 21.09. | ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO | 1 | Reuters | ||
| 21.09. | ADARx Pharmaceuticals strebt bei US-Börsengang Bewertung von 1,74 Milliarden Dollar an | 7 | Investing.com Deutsch |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,370 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,750 | -2,12 % | Arcutis Biotherapeutics, Inc.: Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options | ||
| QIAGEN | 39,115 | -0,48 % | EQS-News: CPT GmbH: Warren Wise entschlüsselt Qiagens DNA | EQS-News: CPT GmbH
/ Schlagwort(e): Research Update/Jahresbericht
Warren Wise entschlüsselt Qiagens DNA
25.09.2026 / 18:15 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 104,83 | +3,07 % | Inhibrx's Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? | ||
| KYMERA THERAPEUTICS | 110,51 | -1,33 % | Kymera Therapeutics auf Stifel-Forum: Schnellerer Entwicklungspfad für führenden Wirkstoffkandidaten | ||
| DYNE THERAPEUTICS | 16,210 | 0,00 % | Positive Studiendaten zu DM1-Mittel treiben Aktie von Dyne Therapeutics an | ||
| RELAY THERAPEUTICS | 18,380 | +5,21 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,290 | -1,80 % | Harmony Biosciences: Oppenheimer bestätigt Rating nach Patentklage | ||
| TANGO THERAPEUTICS | 24,450 | +0,53 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 32,375 | -0,38 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 281,18 | 0,00 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| MINERALYS THERAPEUTICS | 24,460 | -5,41 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| STRUCTURE THERAPEUTICS | 32,690 | -6,77 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,030 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| MODERNA | 179,34 | +3,34 % | Nur noch 4 Spritzen im Jahr?: Dieser Novo-Deal lässt eine kleine Pharma-Aktie um bis zu 161 % explodieren | © Foto: Steffen Trumpf - dpaNovo Nordisk sichert sich exklusiv eine Technologie, die Adipositas- und Diabetesmedikamente künftig deutlich seltener nötig machen könnte. Für Nanexa wird der Deal zum Börsenfeuerwerk... ► Artikel lesen |
ADARX PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 20,635 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADARX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.